Caris Life Sciences Q2 Revenue Jumps 45% to $264M, Nears Breakeven
CAI sits 35% above its 52-week low of $14.19 on elevated volume (2.0× avg).
Summary
Caris Life Sciences reported Q2 2026 revenue of $263.7M (+45% YoY), a near breakeven net loss, and three new product launches. The company refinanced its debt and holds $795M in cash and securities.
Key Events · Earnings and Guidance · CAI
-
Revenue Surges 45% to $264M
Total Q2 revenue reached $263.7M, up from $181.4M a year ago. Molecular profiling services revenue jumped 55% to $252.3M on higher case volumes and improved reimbursement.
-
Near Breakeven Net Loss
Net loss narrowed to $0.6M from $71.8M in Q2 2025. Adjusted EBITDA was $55.7M, a significant swing from $16.7M last year.
-
Three New Product Launches
Caris commercially launched Caris Detect (multi-cancer early detection blood test), Caris ChromoSeq (genomic assay for myeloid malignancies), and Caris MI Clarity (AI-based prognostic tool for breast cancer).
-
Debt Refinancing Completed
On April 1, 2026, Caris refinanced its $400M term loan with a new facility from Blue Owl and Blackstone, extending maturity to 2031 and reducing interest costs. A $25.2M loss on extinguishment was recorded.
Analysis · CAI · Industrial Applications And Services
A standout quarter for Caris Life Sciences. Revenue surged 45% to $263.7 million, fueled by a 55% jump in molecular profiling services as both clinical case volumes and reimbursement rates climbed. The bottom line nearly reached breakeven, with a net loss of just $0.6 million—a dramatic improvement from the $71.8 million loss a year ago. Adjusted EBITDA swung to $55.7 million. The balance sheet remains robust, holding nearly $795 million in cash and marketable securities after refinancing its term loan and extending the maturity to 2031. Three new products launched—Caris Detect for early cancer detection, Caris ChromoSeq for myeloid malignancies, and Caris MI Clarity, an AI-based prognostic tool—broadening the addressable market. The only blemish: a material weakness in internal controls persists, though remediation efforts are underway.
At the time of this filing, CAI was trading at $19.11 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $14.19 to $42.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.